Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 8;13(7):e70611.
doi: 10.1002/ccr3.70611. eCollection 2025 Jul.

Hemiplegic Migraine in a Patient With Neurologic Symptoms After Regadenoson Administration

Benjamin M Moy  1 , Hanna K Bertucci  1 , Betelehem Lemma  1 , Orlyn Rivas  1
Affiliations

Hemiplegic Migraine in a Patient With Neurologic Symptoms After Regadenoson Administration

Benjamin M Moy et al. Clin Case Rep. .

Abstract

Regadenoson, a selective adenosine A2A receptor agonist, is widely used as a stress agent for myocardial perfusion imaging. A2A receptor activation has been implicated in migraines due to its pro-nociceptive effects within trigeminal pain pathways. This case report discusses a 67-year-old female with headache, sudden onset unilateral weakness, and paresthesias after undergoing a PET-CT for ischemic evaluation. Subsequent lab and imaging studies were unconcerning for acute stroke or seizure, raising suspicion for hemiplegic migraine given her extensive neurologic history and rapid onset of symptoms. Regadenoson may be associated with hemodynamic instability and lowering of the seizure threshold. Patients should be screened for neurologic risk factors prior to receiving regadenoson to determine if alternate modalities for ischemic evaluation are more suitable.

Keywords: cardiology; general medicine; migraine; neurology; regadenoson.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Brain MRI sections showing no acute intracranial abnormalities.
FIGURE 2
FIGURE 2
Carotid artery duplex ultrasound images with hemodynamically insignificant disease bilaterally. (A) left proximal common carotid artery (CCA), (B) right proximal CCA, (C) left distal CCA, (D) right distal CCA.
See this image and copyright information in PMC

References

    1. Iskandrian A. E., Bateman T. M., Belardinelli L., et al., “Adenosine Versus Regadenoson Comparative Evaluation in Myocardial Perfusion Imaging: Results of the ADVANCE Phase 3 Multicenter International Trial,” Journal of Nuclear Cardiology 14, no. 5 (2007): 645–658, 10.1016/j.nuclcard.2007.06.114. - DOI - PubMed
    1. Brink H. L., Dickerson J. A., Stephens J. A., and Pickworth K. K., “Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing,” Pharmacotherapy 35, no. 12 (2015): 1117–1123, 10.1002/phar.1669. - DOI - PubMed
    1. Al Jaroudi W. and Iskandrian A. E., “Regadenoson: A New Myocardial Stress Agent,” Journal of the American College of Cardiology 54, no. 13 (2009): 1123–1130, 10.1016/j.jacc.2009.04.089. - DOI - PubMed
    1. Kutryb‐Zając B., Kawecka A., Nasadiuk K., et al., “Drugs Targeting Adenosine Signaling Pathways: A Current View,” Biomedicine & Pharmacotherapy 165 (2023): 115184, 10.1016/j.biopha.2023.115184. - DOI - PubMed
    1. Elsadany M., McMahon S. R., Mehla S., and Duvall W. L., “Hemiplegic Migraine Episode Triggered by Regadenoson,” Journal of Nuclear Cardiology 29, no. 6 (2022): 3469–3473, 10.1007/s12350-021-02736-1. - DOI - PubMed

LinkOut - more resources